Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)



Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million shares in the last session and the average volume of the stock remained 547.74K shares. The beta of the stock remained 1.51. Insys Therapeutics Inc (NASDAQ:INSY) insider ownership is 0.50%.

Ingredients and medical food company, Enzymotec Ltd (NASDAQ: ENZY), is plummeting in the market by a high of 28.57% after the company reported its first quarter unaudited financial results. During the quarter, the company signed a settlement and license agreement with Neptune Technologies & Bio resources. It also completed the repayment of its long-term loan subject to financial and other covenants. Based on consolidation method, net revenues of Enzymotec Ltd (NASDAQ:ENZY) for the quarter increased by 43.5% to $23.7 million up from $16.5 million reported for the same period in 2013. Based on an equity method, revenues should come in at $17.9 million from $13.8 million a year ago, representing a 29.1% increase. Increase in volume sales and higher margin products, as well as the operation, of a new extraction facility enabled the first quarter gross margin improve by 1400 basis points to 61.6%, up from 47.3% a year ago. Enzymotec Ltd (NASDAQ:ENZY) dropped -32.03 percent to $13.75 Wednesday on volume of 2.52million shares. The intra-day range of the stock was $13.60 to $18.46. Enzymotec Ltd (NASDAQ:ENZY) has a market capitalization of $308.90million.

Geron Corporation (NASDAQ:GERN) Director Daniel Bradbury purchased 142,776 shares of the stock in a transaction dated Friday, May 9th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $249,858.00. Following the completion of the purchase, the director now directly owns 142,776 shares in the company, valued at approximately $249,858. Geron Corporation (NASDAQ:GERN)’s stock on May 14, 2014 reported a decrease of -6.44% to the closing price of $1.89. Its fifty two weeks range is $1.05 -$7.79. The total market capitalization recorded $296.61million. The overall volume in the last trading session was 2.22million shares. In its share capital, GERN has 156.94million outstanding shares.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported its 1Q14 earnings for the quarter ended March 31, 2014. The company reported wider net loss for 1Q14 at $16.1 million ($0.17 per share) as compared to a net loss of $11.7 million ($0.14 per share) for 1Q13. The company reported cash equivalents, marketable securities and interest receivable at $144.7 million as at March 31, 2014. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported research and development expenses for 1Q14 at $12.8 million against $8.7 million for 1Q13. The increase in R&D expenses was largely attributed to higher pre-clinical as well as manufacturing costs for ACH-3422 and higher clinical development costs for ACH-2684 and ACH-3102. On Wednesday, shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) dropped -6.57% to close the day at $2.70. Company return on investment (ROI) is % and its monthly performance is recorded as -1.46%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly revenue growth is -26.23%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone